The MTD of the combination was well tolerated and these data support further investigation of azenosertib with gem in pts with R/R osteosarcoma in an upcoming Investigator-Initiated Phase 2 trial.Clinical trial information: NCT04833582.Viswatej Avutu...
179#Background:The phase 3 EMBARK trial demonstrated clinically meaningful improvement in metastasis-free survival and secondary efficacy endpoints with enza mono vs leuprolide alone. Herein, we descriptively report secondary endpoints for enza mono vs leuprolide alone across prior definitive tx subgroups....
Top News
Conclusion Results from the Phase I study show that implementation of a diet rich in prebiotics did not result in adverse events such as increased sepsis, GI GVHD, or C Diff infections and reported a remarkable 1 yr OS It very hard to comply on a daily basis in the first 100 days after...
604O Phase I dose escalation and initial dose expansion results of AMG 193: A MTA-cooperative PRMT5 inhibitor, in patients (pts) with MTAP-deleted solid tumorsdoi:10.1016/j.annonc.2024.08.671A.G. SacherM. Villalona-CaleroB.H. O'Neil...
CTNI-11. A PHASE 1 OPEN-LABEL STUDY OF BRAF INHIBITOR ABM-1310 IN PATIENTS (PTS) WITH RECURRENT BRAF V600-MUTATED PRIMARY CNS TUMORSdoi:10.1093/neuonc/noae165.0378BACKGROUND. ABM-1310 is a blood-brain barrier penetrant BRAF inhibitor. Here we report interim results from our phase 1 study ...
This article proposes a partial transmit sequence (PTS) based on phase selection algorithm (PSA) which selects optimal phase factors for reducing the PAPR of the OFDM signal with less computational complexity. The performance of segmented PTS based on PSA is simulated for 16QAM modulated OFDM ...
In the phase 1/2 CC-92480-MM-002 trial (NCT03989414), MEZI combined with DEX and BORT (MeziVd) or DEX and CFZ (MeziKd) showed meaningful clinical activity and manageable tolerability in pts with RRMM. Here we report updated results with longer follow-up from the MeziVd and MeziKd ...
Olverembatinib As Second-Line (2L) Therapy in Patients (pts) with Chronic Phase-Chronic Myeloid Leukemia (CP-CML)Introduction Olverembatinib (HQP1351), a third-generation BCR-ABL1 TKI, has demonstrated remarkable efficacy and a favorable safety profile in CML pts resistant and/or intolerant ...
CTIM-08. FIRST IN HUMAN STUDY OF THE MRNA-BASED CANCER VACCINE CVGBM IN PATIENTS (PTS) WITH NEWLY-DIAGNOSED AND SURGICALLY RESECTED MGMT-UNMETHYLATED GLIOBLASTOMA (GBM): FIRST RESULTS FROM THE DOSE ESCALATION PHASEdoi:10.1093/neuonc/noae165.0341...